In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.
Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. The ...
In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...
Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...
New York, New York-- (Newsfile Corp. - March 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback